AtriCure, Inc. (ATRC) AI Stock Analysis

Founded in 2000 and headquartered in Mason, Ohio, AtriCure, Inc. develops, manufactures, and distributes advanced medical devices for surgical cardiac tissue ablation and nerve systems globally. Its core products include Isolator Synergy Clamps, multifunctional linear devices like the MAX Pen, and the Coolrail device for longer ablation lines. The company also offers the cryoICE Cryoablation System, the EPi-Sense Guided Coagulation System for atrial fibrillation, the AtriClip System for precise tissue closure, and the suture-based LARIAT System. AtriCure markets its products across the United States, Europe, Asia, and worldwide using direct sales teams and independent distributors.

AtriCure expanded annual revenue from $274.3M in FY2021 to $534.5M in FY2025, recording a 14.9% increase in FY2025. Gross margin has remained steady, printing at 74.4% in FY2025 compared to 75.0% in FY2021. Operating margin improved from -8.6% in FY2024 to -0.6% in FY2025, while net income rose from -$44.7M to -$11.4M. For the trailing twelve months ended June 30, 2026, revenue stood at $569.6M with an operating margin of 6.3% and a profit margin of 1.8%, supported by quarterly revenue growth of 12.8% year over year.

As of June 30, 2026, AtriCure held $167.8M in cash and short-term investments alongside total debt of $71.0M, resulting in net cash of $96.7M. The company shows solid liquidity with a current ratio of 4.22 and a debt-to-equity ratio of 0.14 against $516.4M in shareholders' equity. In FY2025, operating cash flow turned positive to $57.3M, yielding free cash flow of $48.3M. Cash allocation in FY2025 included $9.1M in capital expenditures and $11.2M spent on share buybacks, while the share count increased 8.3% over five years.

AtriCure carries a market cap of $2.85B and an enterprise value of $2.95B. The stock trades at a trailing P/E of 267.0x and a forward P/E of 232.6x, well above the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its enterprise value-to-EBITDA multiple of 75.1x also trades at a premium to the peer median of 12.0x, alongside a price-to-sales ratio of 5.0x versus the peer median of 4.1x. Over the past year, ATRC achieved a return of 50.6%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of -21.4% trails the benchmark's 83.0% gain.

Wall Street analysts hold 4 Strong Buy, 3 Buy, and 3 Hold ratings on AtriCure, with zero Sell or Strong Sell ratings. The mean price target is $55.78, representing a 0.5% discount to the last close of $56.07. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $0.28 on revenue of $606.3M. For the following fiscal year, 9 analysts forecast EPS of $0.43 and revenue of $679.7M. The company beat EPS estimates in all of the last 4 quarters, with its next earnings release scheduled for November 3, 2026.

This page is an AI-written research summary of AtriCure, Inc. (ATRC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ATRC income statement, ATRC balance sheet, ATRC key metrics, ATRC analyst forecast, ATRC chart. See the ATRC stock overview for the latest quote and news.